The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
Germany will be the first launch market
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
Subscribe To Our Newsletter & Stay Updated
